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Abstract
Introduction: Measurement of thrombolytic activity i.e.
clot lysis is crucial for research and development of novel
thrombolytics. It is also a key factor in assessment of the
effectiveness of conventionally used thrombolytic agents
in the clinic, which are the choice effective therapies for
myocardial infarction and ischemic stroke. Previous
methods used for the assessment of thrombolytic activity
are often associated with some drawbacks such as being
costly, time-consuming, complication and low accuracy.
Here, we introduce a simple, economic, relatively
accurate and fast method of spectrophotometric analysis
of thrombolytic activity (SATA) assay, standardized
by tissue plasminogen activator (tPA), which can
quantitatively measure in vitro thrombolytic activity.
Methods: Blood clots were formed, uniformly, by mixing citrated whole blood with partial
thromboplastin time (PTT) reagent, together with calcium chloride. Then, designated concentrations
of tPA were added to the samples, and the released red blood cells from each clot were quantified
using spectrophotometry (λmax= 405 nm) as an indicator of thrombolytic activity. The accuracy of the
method was tested by assessment of dose-responsibility against R2 value obtained by linear equation
and measurement of limit of detection (LOD) and limit of quantification (LOQ). The SATA assay was
validated in comparison with some currently used techniques.
Results: A linear relationship was obtained between different concentrations of tPA versus the
spectrophotometric absorbance of the related dilutions of lysed clots, at λmax = 405 nm. Calculated R2
values were greater than 0.9; with LOD of 0.90 µg/mL of tPA (436.50IU) and LOQ of 2.99 µg/mL of
tPA (1450.15IU).
Conclusions: Conclusively, the SATA assay is a very simple quantitative method with repeatable and
reproducible results for estimating the potency of an unknown thrombolytic agent, and calculating the
activity as delicate as 1 µg/mL of tPA (485 IU/mL of thrombolytic dose).

Introduction
Thrombolytic therapy is the only effective medication for
the myocardial infarction (MI) and brain ischemic stroke,
which are known as the leading causes of mortality and
disability worldwide.1-6 The first thrombolytic agent was
discovered in 1933,7 and then two thrombolytic therapies
were reported in 1949 and 1950.8,9
Numerous thrombolytic agents, comprising of
streptokinase (EC: 3.4.24.29) and tissue plasminogen
activator/s (tPAs; EC 3.4.21.68) have been introduced
for the clinical uses, which may be categorized as

different generations together with various agents,
extracts, technologies and de novo advanced systems.7,10,11
Bioactivity of a thrombolytic agent is not only an
important parameter indicating its potential outcomes in
experimental investigations, but also a vital measure for
the clinical success in critical situations (e.g., cardiac or
brain vascular interventions or thrombolytic therapies).
Thrombolytic agents are usually enzymes whose
functions may be affected by various factors, including
pH, temperature, circumstance and time of maintenance.
Such issues may influence the final clinical outcomes
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of pharmacotherapy, especially during vital vascular
interventions.
Historically, in 1794, the phenomenon of fibrinolysis
was introduced as “the blood-deprived of its coagulation
power”.12 For the first time in the 1950s, euglobulin lysis
assay was developed to measure the natural fibrinolysis.13-15
Subsequently, a variety of methods were developed to
measure the potency of thrombolytic agents for possible
clinical administration. However, the methods in some
cases appeared to be dependent on costly materials and
agents. For instances, a relatively expensive D-dimer
measurement was incorporated in the quantification of
the fibrin degraded particles after lysis.16 Further, fibrin
agarose plate assay (FAPA) needs fibrin, fibrinogen, and
thrombin to be mixed with agarose.17-20 The occluded
tube model needs thrombin to be mixed with the blood
sample,21,22 and the heparin modulated clot lytic activity
needs thrombin together with plasminogen.23 Moreover,
the other un-official methods utilize thrombin.24,25 The
time required for the assessment of thrombolytic enzymes’
activity is a very important factor in the case of emergency
needs in the clinic. Thus, taken all, time is a limiting factor
in these types of experiments.23,26,27 In a method, whole
blood was recruited freshly and incubated at 37°C for 24
hours to form clots spontaneously.28 Although the method
is economic, it is rather time consuming and laborious,
which makes it even more complicated to discriminate
the spontaneous lysis of clot from lysing effect of the
thrombolytic agent. The other problem in the previously
developed methods is that the formed clots always are
irregular along with some un-clotted residues that should
be “aspirated out” or “washed with saline”.26,28
In the present investigation, spectrophotometric
analysis of thrombolytic activity (SATA) assay, that is
actually designed for the measurement of clot lysis, was
developed using partial thromboplastin time (PTT)
reagent together with calcium chloride for the induction
of a uniform and precisely equal clot formation. These
reagents are inexpensive and easy to access, and when
used properly, induce rapid (within several minutes)
regular complete clots from plasma or whole blood
samples. Here, this assay is introduced for the first time
as a simple and non-expensive method for the analysis of
thrombolytic activity in vitro, which could be performed
in any laboratory equipped with a spectrophotometer,
even in a hospital. The method has been established
based on the UV/Vis absorbance of hemoglobin of red
blood cells (RBCs) released from a clot; standardized by
concentrations of standard tissue plasminogen activator
(tPA). Performing the method by visualizing the red
color, instead of the spectrophotometric absorbance of
hemoglobin, makes it possible to have a rough estimate
of the activity of thrombolytic drugs in a clinical setting.
Materials and Methods
Materials and equipment
Buffered sodium citrated tube was purchased from
32
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Persian Lab (Tehran, Iran), sterile water for injection
and normal saline serum as diluent were obtained from
the Iranian Parenteral and Pharmaceutical Company
(Tehran, Iran). Insulin syringe was prepared from SUPA
Medical Devices (Tehran, Iran). The activated partial
thromboplastin time (APTT) reagent was purchased from
the Pacific Hemostasis™ Fisher Scientific (Massachusetts,
USA). Calcium chloride was acquired from Bahar Afshan
(Tehran, Iran). The tissue plasminogen activator (tPA),
Actilyse® (Alteplase), was bought from Boehringer
Ingelheim (Ingelheim am Rhein, Germany).
Blood samples
Human whole blood was collected from cubital vein of
adult volunteers by sterile venipuncture, transferred into
buffered sodium citrate tubes and refrigerated until use.
All volunteers were healthy, without current or previous
hematologic, coagulative or bleeding disorders or recent
abortion; they were not pregnant or on any hormonal
therapy or contraception. The study was conducted as
approved by the Ethics Committee of Tabriz University of
Medical Sciences, and an informed consent was obtained
from volunteers.
Production of blood clots
Clots were formed using 300 µL of citrated whole blood
mixed with 200 µL of PTT reagent and 200 µL CaCl2. Clot
formation was completed in 5-10 minutes. For prevention
of the spontaneous thrombolysis of clots, all reactions
were performed on ice before conducting the SATA assay.
Thrombolytic agent
Commercially available lyophilized tissue plasminogen
activator (tPA) was used as the standard thrombolytic
agent during SATA development. The vial was
reconstituted with sterile water for injection as instructed
by the manufacturer; hence the resulted solution of tPA (1
mg/mL) was used as a stock. The stock was aliquoted and
stored at -80°C until use. According to previous reports,
reconstituted tPA preserves its activity for several months
or a year at -30°C and for long-term (several years) at
-80°C.29-32 Appropriate dilutions were prepared by mixing
volumes of the stock with normal saline (N/S) as needed
in the experiments. Dilutions were made freshly prior to
the experiments and kept at 0-4°C during the experiments.
The tPA activity in terms of international units per
nanogram (IU/ng) was also determined by active human
tPA assay ELISA kit (Oxford Biomedical Research,
Avon Industrial Park, Avon, MA, USA) following the
manufacturer instruction. The assay incorporates
plasminogen activator inhibitor-1 (PAI-1) specific for
human tPA to capture active tPAs and an HRP conjugated
secondary antibody for detection. Briefly, reconstituted
biotinylated PAI-1 was added to 96 wells and the plate
was shaken to ensure mixing. The wells were washed
(3×) with wash buffer, and the standards and samples
were added to the wells in duplicate, and the plate was
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shaken again. Following, the plate was washed (3×)
with wash buffer, and the primary antibody was added
to the wells and the plate was shaken. Then, the wells
were washed and the secondary antibody was included.
Finally, 3,3′,5,5′-Tetramethylbenzidine (TMB) substrate
was added and the plate was shaken for 2-10 minutes. The
reaction was stopped by adding sulfuric acid, and the plate
was read at 450 nm. All shakings were performed at 300
rpm at room temperature for 30 minutes, except the last
shaking which was for 2-10 minutes.
The procedure of SATA assay
Designated dilutions (0, 0.5, 1, 2, 2.5, 5 and 7.5 µg/mL;
equal to 0-3637.5 IU/mL) of tPA were prepared in normal
saline. Then, 100 µL of each dilution was added to the clots
in glass tubes and incubated at 37°C for different time
periods for optimization of incubation (5-20 minutes).
Then, 1 mL of normal saline was carefully added to
the mixture (without destroying the residue clots) to
suspend the liquid lysed clot containing RBCs carrying
their hemoglobin. The suspension was diluted 25 times
with normal saline and the absorbance of the suspension
against the diluent blank was measured at the λmax of 405
nm (the peak absorption of hemoglobin). Finally, the
corresponding standard curve was plotted for different
dilutions using corresponded optical densities.
Precision assessment of SATA assay
Thrombolytic activity based on the percentages of digested
clot (% DC) was assessed,26 with some modifications
during the procedure of blood clots production and
preparation of dilutions and control sample. Standard
dilutions (0-3637.5 IU/mL) of tPA were prepared, and 100
µL of each dilution was added to the clots. The mixtures,
in the labeled pre-weighed microtubes, were incubated
at 37°C for 20 minutes. The weight of the primary clots
and the residue clots after the clot lysis were measured
and used to calculate the percentages of the digested clots
(reduction in clot weight) according to the equation (1)26:

% DC

Weight reduction of the clot
×100
Weight of the primary clot

(Eq. 1)

Moreover, the occluded tube model was used for the
analysis of the thrombolytic activity of tPA as reported
previously.21,22 A transparent tube with a piston and
internal diameter (ID) of 0.5 cm and length of 8 cm (an
insulin syringe), was used for the model development. The
mixture of citrated whole blood, CaCl2, and PTT reagent
were added into the developed tube while the piston was
in the middle, to form the clot in a fixed position along the
tube. After completion of the clot formation, the piston
was detached carefully and a clot which was formed
homogenously without internal void volumes or loose
adhesion inside the tube was used as a proper occluded
tube model to mimic the clotting process in the blood
vessels. One side of the occluded tube was filled with

normal saline and the other side was filled with 300 µL
of different concentrations of the thrombolytic agent. The
two ends of the tube were properly sealed, and the tube
was incubated at 37°C for different time periods. The
appearance of a red color induced by the lysed clot at the
clot surface exposed to normal saline was considered as
the lysis time, while the recanalization time was measured
in the case of formation of a visible channel along the clot.
Troubleshooting and important hints
• When the suspension of the lysed clot is being diluted,
the final volume should be set due to the volume
needed to fill the cuvette of the spectrophotometer.
• The dilutions of the suspension of the liquid lysed
clot were adjusted so that the absorbance would be
in the range (OD ~ 0.5 to 1.7). In the case of low/
high absorbance for any reason (e.g., modifications in
the agent, concentrations, time, etc) dilutions would
better be less/more, respectively.
• After the reconstitution of tPA, it is deactivated after
several hours at room temperature and 24 hours
at 4°C. Therefore, dilutions would better be made
freshly prior to experiments and be kept at 4°C during
the experiments.
• When the clots are formed, they show some
spontaneous thrombolytic activity. To reduce
spontaneous thrombolysis, clots should be kept on ice
or refrigerator before and after the experiments. At the
experimenting time, all clots with their thrombolytic
agent should be incubated at 37°C, and taken from it
at the same time.
• The differences of thrombolytic activity induced by
various concentrations of tPA are rather insignificant
during the first few minutes and also after long times
when high concentrations of tPA have lysed the
clots completely. The optimum time for finding the
significant difference of concentrations in this range
is 15-20 minutes. For continuance of the thrombolysis
process for a longer period, the size of clots should be
larger.
• Clot formation by the current method should be
completed without any residue. Also, the final
volume of all clots (sum of whole blood and reagents)
should be equal in different samples. In the case of
incomplete clot formation, the quantity/quality of
reagents should be checked. Moreover, the blood
should be used during several days after collection,
with normal coagulation (at least with normal
international normalized ratio-INR) and mixed
with a correct proportion of citrate. If necessary, the
amount of reagents could be increased to complete
the clot formation. However, it is recommended that
other mentioned probable problems to be checked
first.
• Sterile water for injection could be used for the
reconstitution of tPA, but not for the dilution or as
the control versus the thrombolytic agents because
BioImpacts, 2018, 8(1), 31-38
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•

low osmolality destructs the clot without activating
thrombolysis. Therefore, we used normal saline as the
diluent in all steps (diluting thrombolytic agent or the
lysed clot).
The clot residues are very delicate and could be
disrupted easily, therefore the first dilution of the
lysed clot must be done as gentle and fast as possible.

Statistical analysis
For statistical analysis, one-way analysis of variance
(ANOVA) and independent Student’s t-test were applied
to compare mean differences of ODs. A P value less than
0.5 was considered statistically significant.
Results
SATA assay
As thrombolysis continues, RBCs are released from the
clot. The thrombolytic activity of various concentrations
of tPA, in the range of 0-7.5 µg/mL (equal to 0-3637.5 IU/
mL), was measured by spectrophotometry of hemoglobin
released from the lysing clot. A standard curve was plotted
for the resulted absorbance values, and the equation
together with R square value was calculated. The limit
of detection (LOD) and limit of quantification (LOQ) of
the method were calculated as well, and the results were
compared with other methods previously introduced for
the measurement of thrombolysis. The ODs obtained
from clots lysed by tPA concentrations are presented in
Fig. 1.
A linear relationship was obtained between different
concentrations of tPA and the spectrophotometric
absorbance of the related dilutions of lysed clots, at λmax
= 405 nm. Calculated R square values were more than
0.9. LOD and LOQ are important characteristics in the
method validation. They are used to describe the smallest
concentration of an analyte that can be reliably measured
by an analytical procedure.33 The mixture and absorption
measurement of the lowest concentration of tPA were
repeated at least 3 times. LOD and LOQ were calculated
as follows:

LOD = 3 ×

SD of the lowest concentration
Slope of the calibration line

LOQ= 10 ×

SD of the lowest concentration
Slope of the calibration line

BioImpacts, 2018, 8(1), 31-38

Precision assessment of SATA assay
To confirm the results obtained from the SATA assay,
thrombolytic activity of different concentrations of tPA
was also measured using conventional measurement of
percent of digested clot. A linear relationship was obtained
for different concentrations of active tPA plotted versus
the related percentages of the digested clots. The standard
curve of the percentages of digested clot is shown in Fig. 4.
Although different concentrations of tPA caused different
percentages of DC, these differences were not statistically
significant.
Besides, for further justification of effectiveness of the
SATA assay, the occluded tube model was carried out as
described previously.20,21 Fig. 5 shows different steps of
the developed model. The model at the beginning of the

Fig. 1. The optical density of clots lysed by different concentrations
of tPA representative of their thrombolytic activity.

(Eq. 2)

(Eq. 3)

As calculated for the SATA assay, the LOD was 0.90
µg/mL of active tPA (436.50 IU) and LOQ 2.99 µg/mL of
active tPA (1450.15 IU). The difference of optical densities
induced by various concentrations of tPA was statistically
significant (P < 0.05). The spectrophotometric absorbance
at a spectrum of 190-700 nm for a dilution of lysed clot
induced by one of the concentrations of tPA was obtained
(Fig. 2). The mentioned linear relationship was in the
corresponding wavelength (Fig. 2, peak no. 3) which
34

is the peak absorption of hemoglobin. In addition, the
differences in the red color of the diluted lysed clots could
be visualized macroscopically, as shown in Fig. 3.

Fig. 2. Spectrum absorbance of a dilution of lysed clot induced by
one of the concentrations of tPA.

Analyzing thrombolysis by SATA

experiment is shown in Fig. 5A. Various concentrations of
tPA could induce complete lysis of the occluding clot; even
the control sample (normal saline free of tPA) induced
complete lysis after nearly 4 hours (Fig. 5D). Table 1 shows
the time of the clot lysis as well as the recanalization and
complete lysis induced by various concentrations of tPA.
The low concentrations of tPA, in the range of 0-10 µg/
mL (0-4850.00 IU), showed a clot lysis pattern similar to
the control. Therefore, higher tPA concentrations were
applied as 50, 150 and 200 µg/mL (24250, 72750 and
97000 IU, respectively).
The activity of the standard concentrations of tPA was
measured by the ELISA method (Fig. 6). The activity of
the drug used in this investigation was about 0.485 IU/
ng, which was utilized for IUs calculation of the tPA used.
Discussion
Analysis of the thrombolytic activity of thrombolytic
agents, that is actually a measurement of clot lysis, is
crucial not only for the research but also for the clinical
applications, including thrombolytic therapies for MI
or ischemic stroke. Methods previously introduced for
the measurement of thrombolytic activity appear to be
associated with some limitations such as being costly, timeconsuming and complex and often with low accuracy. The
measurement of thrombolytic activity by fibrin agarose
plates have already been introduced however, it demands

Fig. 5. The occluded tube model. Panels A, B, C, and D represent
the starting point of the model, the initiation of clot lysis, the
recanalization and completion of the thrombolysis process,
respectively.

Fig. 6. The activity of the standard concentrations of tPA measured
by ELISA method.

Fig. 3. Significant macroscopic differences of lysed clots by
various concentrations of tPA.

Fig. 4. Percentages of the digested clot by various concentrations
of tPA representative of their thrombolytic activity.

expensive materials and is not an exact quantitative
analysis.19 The concentration of fibrin degraded particles
released after clot lysis has been measured by D-dimer
assay which is highly accurate, but it is an expensive
approach.16 The occluded tube model, which simulates
the obstruction of a vessel by a clot, was shown to be
unable of discriminating the lower doses of thrombolytic
agents while requiring expensive materials.21,22 Some
economic methods have also been developed, including
the measurement of percentage of digested clot26 and
RBC release from tiny clots.28 These approaches are
often inaccurate and time-consuming, while some other
methods incorporate complex instruments or expensive
agents.24,25,34
The current investigation introduces the SATA
assay, which provides a simple, economical, relatively
accurate and fast method for quantitative analysis of
the thrombolytic activity. The assay records the optical
density (OD) of the dilutions of the lysed clot at 405 nm,
by simple UV/Vis spectrophotometry. This wavelength is
the peak absorption of the hemoglobin, and it could be a
mean to detect the RBCs which are released from the clot,
as thrombolysis continues. The SATA can be used both for
estimation and comparison of the thrombolytic activities
BioImpacts, 2018, 8(1), 31-38
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Table 1. Time points for the clot lysis, recanalization, and completion by various concentrations of tPA in the occluded tube model

tPA concentration (µg/mL)

tPA activity (IU/mL)

Clot lysis time (min)

Re-canalization time (min)

Complete lysis time (min)

Control (0)

0

36

70

~180-240

50

24250

6

11

134

150

72750

3

11

70

200

97000

3

12

90

Table 2. Various methods for measurement of thrombolytic activity, advantages and disadvantages, a qualitative comparison

Method
SATA assay
Percent of digested clot
Occlusive tube model
RBC release from tiny clots
D-Dimer assessment
Heparin modulated clot lytic activity
ELISA

Cost

Time consumption

Complexity

Accuracy

Ref

Low
Low
Medium
Low
High
Medium
High

Low
High
Medium
High
Unknown
High
High

Low
Low
Medium
Low
Medium
High
High

High
Medium
Low
Medium
Very high
Unknown
Very high

Cuurent study
26
21,22
28
23
16

Oxford Biomedical Research

Table 3. Various methods for measurement of thrombolytic activity in terms of time-effectiveness and accuracy, a quantitative comparison

LOD, LOQ
respectively

Ref

Precise: 3-4
Bedside estimate: <1

0.90, 2.99 µg/mL tPA (436.50, 1450.15IU)

Current study

Percent of digested clot

Previously reported: ~ 6
Modified in this study: 2-3

Previously not reported
In this study: 25.02, 83.42 µg/mL tPA (12134.70, 40458.70 IU)

26

Occluded tube model

Previously not reported
In this study 4-8

Previously not reported
In this study > 50 µg/mL tPA (24250 IU)

21,22

RBC release from tiny clots > 24

Not reported

28

D-Dimer assessment

>6

103.5, 345 IU (calculated by the reported data)

16

ELISA

6-7

Reported 0.006 IU (0-1.77 ng/mL tPA)
In this study: 0.008, 0.027 IU

Oxford
Biomedical
Research

Method

Time consumption (h)

SATA assay

Abbreviations: LOD, limit of detection; LOQ, limit of quantification.

as well as for quantification of the concentration of a
standard thrombolytic agent (e.g., tPA, streptokinase and
urokinase), which could induce similar thrombolysis as an
unknown agent does. The resultant data from the SATA
method showed that the equation calculated for the linear
relationship of ODs versus tPA standard concentrations
displayed a coefficient of determination greater than 0.9
with precise discriminative LOD and LOQ values. These
two values are used to describe the smallest concentration
of analytes that can be reliably measured by an analytical
procedure.33 In this investigation, the LOD and LOQ values
were respectively 0.90 µg/mL and 2.99 µg/mL for active
tPA ( 436.50 IU and 1450.15 IU, respectively). The current
experiment was performed by 0-7.5 µg/mL of active tPA
(0-3637.5 IU/mL). The discrimination power of SATA
assay is well beyond the clinical dose of tPA infusion. For
further comparison with other thrombolytic agents such
as streptokinase, the IUs of thrombolytic agents could
be used. Various potencies of commercial tPA have been
reported as much as 1000-580000 IU/mg. The company
36
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which manufactured the tPA utilized in this experiment
reported the potency of 580000 IU/mg; however, a study
in 1990 reported the potency of marketed tPAs only about
492000 IU/mg.35 The range of IUs discriminated in the
current study is five times smaller than the range reported
previously,26 whose model did not show any significant
difference between three dilutions of streptokinase used.
They only reported the difference between water as the
negative control and dilutions of the thrombolytic agent.
Similarly, we found no significant difference between
percentages of the digested clots by various concentrations
of active tPA. However similar to the SATA assay, the
digested clot experiment could give a standard curve by
linear correlation between the percentages of DC versus
the concentrations of active tPA. However, the differences
between results obtained by the minimum and maximum
concentrations of active tPA is not significant regarding to
the digested clot method (Fig. 4), while these differences
appeared to be substantially significant in the developed
SATA assay (Fig. 1), indicating the accuracy of data

Analyzing thrombolysis by SATA

obtained by SATA in comparison with the digested clot
method.
In addition to the fairly high quantitative and accuracy
capacity, the SATA assay offers some other advantages as
well. First, the clot formation in this assay is completed
within several minutes, while in the other methods this step
is somewhat time-consuming (4-24 hours).23,26,27 Second,
the clot formation is literally completed without any
residue, and the volume of the formed clot is predictable
and manageable. Third, the SATA method incorporates
citrated blood, which could be refrigerated for later use,
while most of the other methods require fresh blood with
its immediate natural clotting capacity.26,28 Overall, the
experiment could be started and terminated at most in
several hours. Based on these findings, the SATA assay
appears to be an economical method that can be executed
using inexpensive reagents and small amounts of the
thrombolytic agent in low concentrations.
Further, the SATA assay could discriminate very low
concentrations of active tPA (<10 μg/mL), while the
occluded tube model could differentiate the concentrations
higher than 50 μg/mL. However, as a model simulating
the in vivo vascular obstruction and recanalization,
the occluded tube model reserves the value of farther
translational interpretation of in vitro thrombolytic
activities to clinical outcomes in thrombolytic therapies
of MI or ischemic stroke. Ultimately, the measurement of
tPA activity by ELISA was actually performed as the gold
standard. ELISA method is extremely accurate and could
discriminate active tPA concentrations as low as 0.01 ng/
mL. As instructed by the manufacturer of the ELISA kit,
the standard concentrations were prepared according to
IU/mL of tPA (i.e., 0-1 IU/mL equal to 0-1.77 ng/mL).
Despite this high accuracy, there is no doubt that ELSA,
especially for this purpose, possesses many limitations,
including significant time consumption, high cost,
complexity while many facilities are needed. Moreover,
this method directly assesses the concentration of active
enzymes and not an ultimate output of thrombolysis.
Historically, fibrinolysis was discovered through many
observations including the fact that blood collected by
wet-cupping (several milliliters) might be clotted and then
spontaneously dissolved in 12-24 hours.36 Whole blood
certainly possesses potency of lysing clot per se, and this
potency originates from the natural blood thrombolytic
agents. Thus, it is not of surprise that the control samples
with zero concentration of active tPA exhibit clot lysis to
some extents in all methods developed for thrombolytic
activity measurement, including the developed SATA
assay and the digested clot method. However, it is of
wonder that, to the best of our knowledge, in the previously
described methods spontaneous thrombolysis in control
sample was rarely mentioned.
Comparison of SATA with other methods developed
previously is summarized in Table 2 and Table 3.
The SATA assay is a simple approach that can be

Research Highlights
What is current knowledge?
√ Measurement of thrombolytic activity is crucial for research
and development of novel thrombolytics.
√ Previous methods used for this measurement are often
associated with some drawbacks including cost, timeconsumption, complexity and low accuracy
What is new here?
√ Here, the SATA assay is introduced for measuring in vitro
thrombolytic activity.
√ SATA is a very simple quantitative method with repeatable
and reproducible results, economic, relatively accurate and
fast, with LOD of 0.90 µg/mL of tPA (436.50IU) and LOQ of
2.99 µg/mL of tPA (1450.15IU).

performed for clarifying the tPA activity prior to clinical
administration (bedside) in thrombolytic therapies
of MI or ischemic stroke, by simple instruments and
visualization of the difference of red color in dilutions even
though with some degree of lower accuracy. However,
such utility of the SATA assay in a clinical setting is just
for further confirmation of thrombolytic activity of a
drug with a rough estimation. Nevertheless, the SATA
assay, if performed in hospital laboratories equipped
with spectrophotometry, can provide a quite accurate
thrombolytic activity value of clinically used drugs.
Conclusion
The established SATA assay is a simple and cost-effective
method with high precision and accuracy that can be
conducted quantitatively and fast for in vitro measurement
of thrombolytic agents’ activity. This method is able
to discriminate less than 10 µg/mL of active tPA (4850
IUs), which is thousands of times less than the clinical
dose of tPA. The method could be used for comparing
the thrombolytic activities of thrombolytic agents and
measurement of the potency of unknown thrombolytic
agents with some degree of high accuracy for investigations
and clinical assessments.
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